Nektar/Bayer Agree To Develop Inhaled Amikacin For Hospital-Acquired Pneumonia
This article was originally published in The Pink Sheet Daily
Executive Summary
Product combining Nektar’s deep-lung delivery technology and amikacin formulation could reach market in 2010-2011 timeframe, Nektar COO tells “The Pink Sheet” DAILY.